ClinicalTrials.gg
Active, not recruitingNCT05222984Updated Oct 14, 2026

Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

A Phase 1 interventional study of Decitabine and Navitoclax in Recurrent Acute Myeloid Leukemia and Refractory Acute Myeloid Leukemia, sponsored by City of Hope Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment

How we know

Updated Oct 14, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 121 studies testing decitabine in Leukemia, Myeloid, Acute — 20 open to participants now, 33 under way, 2 of them phase 3. Decitabine · Leukemia, Myeloid, Acute.

Enrollment
87th of 120
17 · median 32
Started
2022
with 6 others
Phase 1
37 of 121
6 open now
Primary completion
2027-03
later than 14 of 32 live
Registered
99th of 121
by date

Among the 121 studies testing decitabine in Leukemia, Myeloid, Acute, this one is the 87th largest by enrollment of the 120 interventional ones that give a count, is one of 7 that started in 2022, is one of 37 in phase 1, reaches primary completion later than 14 of the 32 other live ones, and was the 99th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

20 of the 121 studies testing decitabine in Leukemia, Myeloid, Acute are open now, in 5 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About decitabine

Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies testing decitabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This phase Ib trial is to find the side effect and best dose of navitoclax when given together with venetoclax and decitabine in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory) after previous treatment with venetoclax. Chemotherapy drugs, such as navitoclax, venetoclax, and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Read the detailed description

PRIMARY OBJECTIVES:

I. Assess safety and determine the optimal biological doses (OBD). II. Evaluate the anti-leukemic activity, as assessed by overall response rate (ORR: complete response [CR] + complete response with incomplete hematopoiesis [CRi] + partial response [PR]) within the first 35 days (cycle 1).

SECONDARY OBJECTIVES:

I. Characterize safety and tolerability of navitoclax/venetoclax during the first 7 days of cycle 1.

II. Obtain preliminary estimates of:

IIa. Overall response (CR+CRi+PR) duration. IIb. Progression free survival (PFS) and overall survival (OS) rates at 6-months and 1-year.

CORRELATIVE STUDY OBJECTIVES:

I. Describe the anti-leukemic activity (i.e. decrease in percent blasts) of navitoclax/venetoclax as assessed by disease in bone marrow (BM) and/or peripheral blood (PB).

II. Explore the potential relationship between changes in BH3 protein expression profiles (pre- and post-treatment) and response.

III. Profile the clonal evolution of acute myeloid leukemia (AML) in response to treatment by single cell next generation sequencing (NGS) of whole exomes and the ribonucleic acid (RNA) transcriptome.

IV. Profile the clonal evolution of AML in response to treatment by single cell NGS of the mitochondrial genome.

V. Determine mitochondrial number and heteroplasmy and changes in response to treatment.

VI. Determine the impact of treatment on leukemic stem cell (LSC) burden by examining bone marrow (BM)-derived mononuclear cells (MNC) for their ability to initiate leukemia in in vivo mouse models pre- and post-treatment.

OUTLINE: This is a dose-escalation study of navitoclax.

Patients receive venetoclax orally (PO) once daily (QD) and navitoclax PO QD on days 1-35, and decitabine intravenously (IV) over 1 hour on days 8-12 of cycle 1. Starting on cycle 2, patients receive venetoclax PO QD and navitoclax PO QD on days 1-28, and decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 1 year.

03

Conditions studied

  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented of the participant and/or legally authorized representative
  • For participants under the age of 18 years, documentation of adolescent assent by the participant and consent of both parents or guardian
  • Adults aged >= 18 years
  • Adolescent patients aged >= 16 years and \< 18 years weighing at least 45 kg who have no other standard-of-care option for treatment
  • (ECOG) =\< 2
  • Patients with confirmed AML, according to World Health Organization (WHO) criteria, with /relapsed (R/R) disease following a venetoclax-containing regimen who are ineligible for therapies known to be effective for treatment of their AML.

    • Patients with extramedullary disease may be included if they also have marrow involvement
    • Patients with acute promyelocytic leukemia (APL) will not be eligible
  • Fully recovered from the acute toxic effects (except alopecia) to =\< grade 1 of prior anti-cancer therapy
  • Ability to swallow pills
  • (ANC) >= 750/mm\^3 (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)

    • NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
  • White blood cell (WBC) =\< 25 x 10\^9/L prior to initiation of study therapy. Cytoreduction with hydroxyurea prior to treatment and/or during cycle 1 may be required (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)
  • >= 75,000/mm\^3

    • NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement
  • Total =\< 1.5 X (ULN) (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)
  • (AST) =\< 3.0 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)
  • Alanine aminotransferase (ALT) =\< 3.0 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)
  • of >= 45 ml/min per 24-hour urine test or the Cockcroft-Gault formula (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)
  • If in the absence of anticoagulants: (INR) OR prothrombin (PT) =\< 1.5 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)
  • If in the absence of anticoagulants: Activated partial thromboplastin time (aPTT) =\< 1.5 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)
  • (LVEF) >= 50%

    • Note: To be performed within 28 days prior to day 1 of protocol therapy
  • interval (QTc) =\< 480 ms

    • Note: To be performed within 28 days prior to day 1 of protocol therapy
  • Seronegative for (HIV) antigen (Ag)/antibody (Ab) combo, virus (HCV), active virus (HBV) (surface antigen negative), and syphilis (RPR) (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)

    • If positive, Hepatitis C RNA quantitation must be performed
  • Meets other institutional and federal requirements for infectious disease titer requirements

    • Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy
  • Women of (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)
  • Agreement by females and males of childbearing potential to use an effective method of or abstain from heterosexual activity for the course of the study through at least 3 months (males) and 6 months (females) after the last dose of protocol therapy

    • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

Exclusion criteria

Exclusion Criteria:

  • Hematopoietic stem cell transplant within 100 days prior to day 1 of protocol therapy
  • Chemotherapy, radiation therapy, biological therapy, or immunotherapy within 14 days or 5 half-lives, whichever is shorter, prior to day 1 of protocol therapy with the following exceptions:

    • Subjects will be allowed to have been on venetoclax at screening and remain on it through treatment start.
    • Hydroxyurea is allowed prior to treatment and through cycle 1 for control of rapidly progressing leukemia
  • Strong or moderate inducers within 14 days prior to day 1 of protocol therapy
  • Grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or star fruit consumed within 3 days prior to the first dose of study drug
  • ( =\< 10 mg/day of oral prednisone or equivalent is allowed) within the last 28 days
  • Hematopoietic growth factors in the last 14 days
  • Must not have received or planning to receive while being on study or 4 weeks before and after completion of treatment
  • Herbal medications known to affect function within 14 days of therapy initiation
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
  • Active graft-versus-host-disease ()
  • Active central nervous system (CNS) disease
  • No in the bone marrow
  • Active diarrhea
  • Gastrointestinal disorder that interferes with oral drug absorption such as malabsorption syndrome
  • cardiac morbidities (class III/IV cardiovascular disability according to the classification, arrhythmia not stable on medical management, acute cardiovascular ischemic event within 6 months of enrollment, etc.)
  • Clinically significant uncontrolled illness
  • Active infection requiring antibiotics
  • Active/uncontrolled infection, acquired immunodeficiency syndrome (AIDS), or currently taking medications for HIV control
  • Diagnosis of Gilbert's disease
  • Any other active at time of enrollment. Exceptions include basal/squamous cell carcinoma, in situ adequately treated breast and uterine cancer
  • Females only: Pregnant or breastfeeding
  • Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Treatment (navitoclax, venetoclax, decitabine)

    Patients receive venetoclax PO QD and navitoclax PO QD on days 1-35, and decitabine IV over 1 hour on days 8-12 of cycle 1. Starting on cycle 2, patients receive venetoclax PO QD and navitoclax PO QD on days 1-28, and decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

    Drug: Decitabine · Biological: Navitoclax · Drug: Venetoclax

Interventions

  • Given IV

    Also known as: 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine

  • BiologicalNavitoclax

    Given PO

    Also known as: A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263

  • Given PO

    Also known as: ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Will be assessed and graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: Up to 1 year

Secondary outcomes

  1. Overall response rate

    Will be calculated as the percent of evaluable patients that have confirmed complete response (CR) or complete response with incomplete hematopoiesis or partial response. Assessment of disease response will be made according to European LeukemiaNet criteria.

    Time frame: Up to 1 year

  2. Progression Free Survival (PFS)

    From the start of study treatment to the time of disease relapse, progression or death from any cause, whichever comes first. assessed up to 1 year

    Time frame: Assessed up to 1 year

  3. Overall Survival (OS)

    Time from the start of study treatment to death from any cause.

    Time frame: Assessed up to 1 year

  4. Dose Limiting Toxicity (DLT)

    DLT will be evaluated in the first 35 days of treatment in the safety cohort to determine any dose limiting toxicities at this dose.

    Time frame: Up to 35 days (1 cycle)

Other outcomes

  1. Change in percent blasts in bone marrow

    Anti-leukemic activity (i.e. decrease in percent blasts) of navitoclax/venetoclax as assessed by disease in bone marrow (BM).

    Time frame: Baseline up to 1 year

  2. Change in percent blasts in peripheral blood

    Anti-leukemic activity (i.e. decrease in percent blasts) of navitoclax/venetoclax as assessed by disease in peripheral blood (PB).

    Time frame: Baseline up to 1 year

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Mar 2027, 53 months after the start.

Of 307 non-industry phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 87. This study's planned 53 months is close to that.

Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

Start moved once since we started tracking on Sep 25, 2026: Jul 2022 → Sep 2022, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2022
First posted
Feb 3, 2022
StartActual
Sep 16, 2022was Jul 2022
Primary completionEst.
Mar 2, 2027
CompletionEst.
Mar 2, 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 29, 2022→Sep 16, 2022
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Start date Jul 29, 2022→Sep 16, 2022
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05222984
Responsible party
Sponsor
First posted
Feb 3, 2022
Start date
Sep 16, 2022
Primary completion
Mar 2, 2027 (estimated)
Completion
Mar 2, 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

Anthony Stein, MD
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Decitabine · Navitoclax · Venetoclax

Start the discussion